Figure 2.
Progression-free survival and OS. Kaplan-Meier curves demonstrating improvement in PFS (A) and OS (B) with ibrutinib and ibrutinib plus rituximab compared with bendamustine plus rituximab.

Progression-free survival and OS. Kaplan-Meier curves demonstrating improvement in PFS (A) and OS (B) with ibrutinib and ibrutinib plus rituximab compared with bendamustine plus rituximab.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal